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ABSTRACT
Treatment options for high grade urothelial cancers are limited and have 
remained largely unchanged for several decades. Selinexor (KPT-330), a first in class 
small molecule that inhibits the nuclear export protein XPO1, has shown efficacy as a 
single agent treatment for numerous different malignancies, but its efficacy in limiting 
bladder malignancies has not been tested. In this study we assessed selinexor-
dependent cytotoxicity in several bladder tumor cells and report that selinexor 
effectively reduced XPO1 expression and limited cell viability in a dose dependent 
manner. The decrease in cell viability was due to an induction of apoptosis and cell 
cycle arrest. These results were recapitulated in in vivo studies where selinexor 
decreased tumor growth. Tumors treated with selinexor expressed lower levels of 
XPO1, cyclin A, cyclin B, and CDK2 and increased levels of RB and CDK inhibitor p27, 
a result that is consistent with growth arrest. Cells expressing wildtype RB, a potent 
tumor suppressor that promotes growth arrest and apoptosis, were most susceptible 
to selinexor. Cell fractionation and immunofluorescence studies showed that selinexor 
treatment increased nuclear RB levels and mechanistic studies revealed that RB 
ablation curtailed the response to the drug. Conversely, limiting CDK4/6 dependent 
RB phosphorylation by palbociclib was additive with selinexor in reducing bladder 
tumor cell viability, confirming that RB activity has a role in the response to XPO1 
inhibition. These results provide a rationale for XPO1 inhibition as a novel strategy 
for the treatment of bladder malignancies.
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INTRODUCTION
Bladder cancer is expected to account for ~17,240 
deaths in the US in 2018 [1]. Bladder cancers can be 
stratified as non-muscle invasive bladder cancer (NMIBC), 
which is confined to the mucosa, and muscle invasive 
bladder cancer (MIBC). While the majority of NMIBCs 
respond well to therapy (typically transurethral resection 
followed by BCG intravesical therapy), MIBC have 
proved more difficult to treat [2]. Cisplatin remains a key 
component of both GC (gemcitabine and cisplatin) or 
the MVAC (methotrexate, vinblastine, doxorubicin, and 
cisplatin) chemotherapy regimens but disease recurrence 
leading to death is common [3]. The recent identification 
of PD-1/PD-L1 inhibitors as an effective therapy for MIBC 
patients is the first addition to the armamentarium for the 
treatment of this malignancy in many years [4]. Identifying 
additional alternative treatments is critical for reducing the 
morbidity and mortality in patients with this disease. 
Exportin-1/chromosome region maintenance 1 
(XPO1/CRM1, referred to hereafter as XPO1), a well-
characterized nuclear export protein, is involved in the 
export of many proteins and RNAs from the nucleus 
[5, 6]. In non-transformed cells the import and export 
of proteins is regulated through various processes and 
dysregulation of nuclear transport has been associated with 
carcinogenesis. XPO1 is instrumental in the nuclear export 
of numerous tumor suppressors and cell cycle regulators 
including retinoblastoma (RB). It is thought that excessive 
nuclear export may be a factor in the development of 
cancer and resistance to chemotherapy [7]. 
The RB family of pocket proteins, RB, p107 and 
p130, interact with E2F transcription factors to repress 
transcription [8, 9]. Phosphorylation of pocket proteins 
during cell cycle progression results in their dissociation 
from the E2Fs allowing them to function as transcriptional 
transactivators [8]. Deregulation of RB by mutations, 
deletions, epigenetic silencing, hyperphosphorylation or 
mis-localization is a common feature of malignancies 
[10]. Hyperphosphorylation of RB can be due to increased 
cyclin levels, particularly cyclin D, which in complex 
with cyclin dependent kinase (CDK) 4/6 predominantly 
targets RB. Similar alterations in p107 and p130 are less 
common [11], but several studies, including ours, reported 
a mislocalization of p130 to the cytoplasm in some tumors 
[12–14]. 
Bladder malignancies harboring RB mutations, 
including loss of heterozygosity, were reported almost 30 
years ago [15, 16]. Reintroduction of RB into bladder cancer 
cells reduced tumor formation frequency [17] decreased cell 
proliferation, and was prognostic for poor outcome [18]. 
Subsequent studies reported that RB hyperphosphorylation 
resulted in inactivation of this tumor suppressor pathway 
[19]. A more recent study of 413 high grade muscle invasive 
bladder malignancies found that the RB gene, RNA or 
protein expression was altered in 17% of the malignancies 
[20]. Bladder malignancies with alterations in the RB and 
p53 pathways have been noted to have high proliferation 
rates [21]. In addition to a mutation, deletion or epigenetic 
silencing of the RB gene, the RB tumor suppressive 
pathway can be circumvented by overexpression of 
cyclin D, Cyclin D which along with its binding partners 
CDK4/6 hyperphosphorylates RB, thus disabling its tumor 
suppressive activity. Alternatively, CDK inhibitor deletions 
or mutations have similar effects, where cyclin/CDK 
activity, and subsequently RB phosphorylation is elevated. 
While mutated or deleted RB cannot be replaced, preclinical 
studies utilizing CDK4/6 inhibitors have shown that these 
compounds have efficacy in retarding growth of certain 
bladder tumors in an RB dependent manner [22].
Previous reports show that selinexor (KPT-330), a 
selective inhibitor of nuclear export (SINE) is an effective 
and specific inhibitor of XPO1 and a putative new 
therapeutic for the treatment of multiple malignancies [23]. 
In silico, in vitro and in vivo studies reported here show 
that XPO1 is expressed in most bladder malignancies, 
and that selinexor effectively reduces XPO1 expression 
and cell viability in a dose dependent manner in all cells. 
Mechanistic studies reveal that the drug induces cell cycle 
arrest and apoptosis, and that the RB/E2F network is a 
component of the response to selinexor. These studies 
show that this drug may be an effective strategy for 
inhibiting MIBC tumor growth. 
RESULTS
XPO1 is elevated in bladder tumor cells 
A review of Oncomine datasets identified two studies 
which showed highly statistically significant increases 
of XPO1 expression in bladder tumors when compared 
with control tissue (Figure 1A). Additionally, TCGA (The 
Cancer Genome Atlas) data, indicated that there was an 
increase in XPO1 gene copy number in cancer tissue. 
There are three additional studies reported on Oncomine 
where XPO1 transcripts are elevated, and P values trended 
toward significance (0.058 to 0.102). There is one study 
that shows no significant increase in XPO1 levels. Taken 
together the data indicate that there is an increase in XPO1 
expression in bladder malignancies. 
To assess XPO1 protein levels in clinical tumor 
samples, archival MIBC tumor tissues were used to 
construct a tissue array. The bladder tumor tissue array 
consisting of 53 high grade urothelial carcinomas was 
used to determine XPO1 expression (Table 1). The age 
of the bladder cancer patients ranged from 36 to 85 with 
an average of 65.7. There was a marked gender disparity 
where 44 of the tumors were from males and 9 were from 
females. Most of the tumors were urothelial carcinomas 
and all tumors were high grade. XPO1 staining was 
detected in the nucleus and in the cytoplasm. There was a 
variation in the intensity of staining in these compartments 
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between tumor samples. Previous studies reported that 
XPO1 can be present in the nucleus and the cytoplasm 
[24, 25]. In Figure 1B, tumor 1 is representative of tumors 
with low levels of cytoplasmic and nuclear staining. Tumor 
2 represents tumors with intense nuclear staining, but 
minimal cytoplasmic staining. Tumor 3 represents tumors 
with strong XPO1 staining in most nuclei and cytoplasm. 
Staining was not detected in non-tumor bladder tissue. 
In robustly staining cells, XPO1 was predominantly 
nuclear. High levels of XPO1 staining were detected in 
one or both compartments in 70% of the tumors, while 
low levels were detected predominantly in the cytoplasm 
in 30% of the tumors. There was no correlation between 
XPO1 expression and gender, age, tumor type or stage. 
We accessed XPO1 expression in 13 bladder tumor 
patient derived xenografts generated from high grade 
malignancies that were established by our colleagues at 
UC Davis [26]. Nuclear XPO1 staining was detected in all 
samples (Figure 1B). 
XPO1 protein levels were assessed in 4 MIBC 
tumor derived cell lines (T24, TCCSUP, J82, and UM-
UC-3) and in a non-transformed but immortalized bladder 
epithelial cell line (SV-HUC1) by immunofluorescence 
(IF) and western blot analyses (Figure 1C and 1D). 
Immunofluorescence studies showed that XPO1 expression 
was predominantly nuclear but were also detected in the 
cytoplasm. The intensity of XPO1 staining was normalized 
to DAPI (Figure 1D). Western blot analyses (Figure 1E) 
were also used to assess XPO1 protein levels, where 
expression was normalized to tubulin. Both indicate 
that XPO1 expression is lowest in SV-HUC-1 cells. Not 
unexpectedly, normalization to DAPI and tubulin give 
somewhat different results. This is most likely due to 
differing levels of tubulin in the different cells. 
Figure 1: Expression of XPO1 in bladder tumor cells. (A) XPO1 expression in normal and bladder cancer from the indicated 
ONCOMINE datasets. The top and bottom of the box indicates the 75th and 25th percentile, respectively. Number of samples (n) and 
p-values (determined by a two-tailed Mann-Whitney U test) are as shown. (B) Representative images of XPO1 IHC staining of primary 
high-grade bladder malignancies (upper panels) and two PDX tumors. 40× magnification. Cells were counter-stained lightly with H&E. 
(C) Immunofluorescent analysis of XPO1 expression (green) in bladder tumor cells, where tubulin staining (red) and DAPI staining (blue) 
served to define the cytoplasmic and nuclear compartments, respectively. The analyses were conducted at the same time with the same 
reagents. (D) Quantification of immunofluorescence where XPO1 levels were normalized to DAPI. (E) Western immunoblot analysis of 
XPO1 expression, where tubulin served as a loading control (upper panel). Normalization of XPO1 expression to tubulin (lower panel, 
intensity to XPO1/intensity of tubulin). The studies were repeated at least once. Error bars denote standard deviation. Student’s t test.
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Selinexor reduces XPO1 expression and 
attenuates bladder tumor cell viability 
Previous studies have reported that selinexor interacts 
with XPO1, which results in a reduction of XPO1 levels 
and in tumor cell viability [27]. Dose response studies 
were conducted to define the sensitivity of various bladder 
tumor cells to selinexor. Cells were treated with vehicle 
or varying concentrations of selinexor for 72 hours. In all 
lines tested, cell viability decreased in a dose dependent 
manner (Figure 2A). Selinexor was particularly effective 
in reducing cell viability of T24 and UM-UC-3 cells where 
0.1 uM reduced cell viability by ~50%. The longer-term 
colony formation assays complimented the CCK-8 assay 
and confirmed cell sensitivity to selinexor (Figure 2B). 
To assess the effect of selinexor on XPO1 levels, cells 
were treated with vehicle (DMSO) or 0.1 uM selinexor 
for 72 hours and subjected to IF or western immunoblots 
analyses. IF studies showed a decrease in XPO1 levels in 
all cell lines (Figure 2D and 2E) and western immunoblot 
analysis confirmed these results (Figure 2C). 
Selinexor induces a cell cycle arrest and 
apoptosis 
While viability studies indicated that selinexor 
reduces cell viability, the analyses did not differentiate 
between a cell cycle arrest and an increase in apoptosis. 
Flow cytometry was used to determine the effect of 
selinexor on cell cycle (Figure 3A). Cells were treated with 
vehicle or 0.1 uM selinexor for 72 hours, fixed, stained 
with propidium iodide, and subjected to flow cytometry. 
All cell lines except TCCSUP exhibited a G1 arrest. A 
statistically significant decrease in S phase was apparent 
in all cells. Moreover, T24 and J82 cells also exhibited a 
decrease in G2/M phase. Hence, XPO1 inhibition retards 
cell cycle progression. Western immunoblot studies 
show that selinexor treatment elevates p27 expression in 
some, but not all cells. Furthermore, selinexor treatment 
decreases cyclin A and cyclin B expression in all but 
TCCSUP cells. Elevation of p27 and reduction of S phase 
cyclins is consistent with a decrease in proliferation. 
(Figure 3B).
Table 1: Patient and tumor characteristic
Number XPO1 medium/high XPO1 low
Total 53 38 15
Gender
  Female 9 6 3
  Male 44 32 12
Age range: 36–85; average: 65.7
 under 60 16 11 5
 60–69 13 10 3
 70 and over 25 17 8
Race
  not listed 17 12 5
  African American 1 1 0
  Asian 1 0 1
  Caucasian 34 25 9
   Caucasian Hispanic 4 4 0
   Caucasian non Hispanic 30 21 9
Tumor type
  not reported 1 1 0
  Papillary urothelial carcinoma 13 9 4
  SCC 1 1 0
  Urothelial Carcinoma 38 27 11
Grade
 High grade 50 35 15
 Low grade 2 2 0
 unknown 1 1 0
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Two different methods were used to determine if 
selinexor induces an apoptotic response. Cells treated 
with vehicle or selinexor for 72 hours were subjected to 
a cleaved caspase 3/7 immunofluorescent assay. All cell 
lines exhibited a dose-dependent increase in caspase 3 
and 7 cleavage (Figure 3C and 3D). Western immunoblot 
analysis was conducted to detect PARP cleavage, a well-
documented marker of apoptosis (Figure 3E). Dose 
dependent increases in cleaved PARP were evident in all 
cell lines treated with the drug. Notably, selinexor induced 
apoptosis at the 0.1 uM concentration in all cells except 
TCCSUP. Taken together, the data demonstrates that 
selinexor elicits a growth arrest and an apoptotic response 
in several models of bladder cancer. 
The in vivo efficacy of selinexor was assessed in a 
xenograft study using UM-UC-3 cells. Cells (106) were 
implanted into the flank of athymic female mice. Once 
tumors were apparent, mice were treated with either 
Figure 2: Selinexor reduces bladder tumor cell the viability. (A) Cell viability assays of four bladder tumor cell lines treated 
with different concentrations of selinexor for 72 hours. Error bars denote standard deviations. (B) Colony formation assays of four cell 
lines treated with 0.1 uM selinexor or vehicle for T24-12 days, UM-UC-3-11 days, J82-9 days and TCCSUP-10 days. At the end of the 
study, the cells were fixed with methanol and stained with crystal violet. (C) Expression of XPO1 in bladder tumor cell lines treated with 
0.1 uM selinexor for 72 hours analyzed by Western immunoblots. Tubulin serves as a protein loading control. V = vehicle, S = selinexor. 
(D) Immunofluorescent detection of XPO1 (green) in cells treated with vehicle and selinexor. Cells were plated on chamber slides and 
they were treated with either vehicle or selinexor for 48 hours. Tubulin (red) and DAPI (blue) served to define the nuclear and cytoplasmic 
compartment, respectively. (E) Quantitation of XPO1 expression normalized to DAPI. *denotes p ≤ 0.05, **denotes p ≤ 0.01. S.E.M.
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vehicle (5 mice) or 15 mg/Kg of selinexor (7 mice) by oral 
gavage 3 times per week, a dosing schedule reported to be 
effective in reducing growth of other tumor types [28–30]. 
The growth rate for each tumor was followed 3 times per 
week over the course of the experiment. Treatment with 
selinexor significantly impaired tumor growth (Figure 4A; 
growth rate of each individual tumor and Kaplan–Meier 
survival data in Supplementary Figure 1). Mice were 
weighed twice per week and selinexor treated mice did not 
exhibit a weight loss, or any discernable adverse effects. 
After mice were euthanized the tumors were excised and 
flash frozen. The weight of tumors from selinexor treated 
mice was significantly smaller than the weight of tumors 
from vehicle treated mice (Figure 4B). One of the selinexor 
treated mouse tumors was too small to obtain sufficient 
tumor tissue for analysis. Western immunoblot analyses of 
tumor tissue extracts indicate that drug treatment reduced 
XPO1 expression (Figure 4C). Furthermore, elevation 
of RB and p27 and reduction of cyclin A, cyclin B, and 
CDK2 in selinexor treated tumors confirms that selinexor 
impairs tumor cell proliferation in vivo. 
XPO1 inhibition increases wildtype RB nuclear 
levels 
Previous studies have shown that XPO1 is important 
for the nuclear export of several tumor suppressors 
including RB [31, 32]. Of the four bladder tumor cell lines 
studied, T24 and UM-UC-3 cells express wildtype (wt) 
RB [33]. RB is deleted in TCCSUP cells and is mutated 
and expressed at very low levels in J82 cells [33–37]. All 
four cell lines express RB related proteins, p107 and p130. 
Two different techniques were used to study 
expression levels and localization of the pocket proteins. 
IF was used to analyze RB, p107 and p130 expression 
in cells treated with vehicle or selinexor. Co-staining 
Figure 3: Selinexor induces cell cycle arrest and apoptosis. (A) Cell cycle analysis of selinexor treated cells was assessed by 
flow cytometry. Cells were treated with vehicle (red) or 0.1 uM selinexor (blue) for 72 hours. (B) Expression of XPO1, cyclin A, cyclin B, 
and p27 in cells treated with vehicle (V) or 0.1uM selinexor (S) was assessed by Western immunoblot studies. Tubulin served as a loading 
control. (C) Cells were treated with two different doses of selinexor for 72 hours and followed by caspase3/7 immunofluorescence assays. 
(D) The extent of apoptosis detected by the caspase 3/7 assay was quantified by counting 4 separate fields and shown as fold increase over 
control. (E) Detection of PARP cleavage in cells treated with vehicle or increasing doses of selinexor for 72 hours by Western blot analysis. 
Arrow points to cleaved PARP. Tubulin served as a loading control. *denotes p ≤ 0.05, **denotes p ≤ 0.01. Error bars denote standard 
deviation; Student’s t test.
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with tubulin antibodies (red) and DAPI (blue) identified 
the cytoplasmic and nuclear compartments, respectively 
(Figure 5A). RB expression was exclusively nuclear 
whereas p107 and p130 expression was mostly nuclear 
and faintly cytoplasmic in some cells. Nuclear expression 
of p130 was affected by drug treatment in T24 cells. p107 
expression was unchanged in TCCSUP and T24 cells 
but was elevated in J82 and UM-UC-3 cells. RB levels 
were extremely low in J82 cells. UM-UC-3 and T24 cells 
have higher levels of RB, which were further augmented 
by selinexor treatment. The expression levels of pocket 
proteins were quantified and standardized to DAPI 
staining (Figure 5B).
Subcellular localization of the pocket proteins 
was additionally evaluated by cell fractionation 
studies. Successful fractionation was confirmed by the 
analysis of tubulin, a cytoplasmic marker, and Nup62, 
a nuclear marker (Figure 5C). These studies show that 
RB expression is exclusively nuclear while p107 and 
p130 is mostly nuclear but detected in the cytoplasmic 
compartment in some cells. Treatment with selinexor 
increased nuclear levels of RB in T24 and UM-UC-3 cells. 
Selinexor did not affect mutant RB in J82 cells. There was 
a small increase in the nuclear levels of p107 and p130 in 
some cells, along with a shift in the ratios of cytoplasmic/
nuclear levels of these proteins. The fractionation studies 
Figure 4: UM-UC-3 cell xenograft growth is retarded by Selinexor. (A) 106 UM-UC-3 cells were re-suspended 1:1 in 
Matrigel:PBS and injected into the left flank of female athymic nude mice. 5 mice were treated with vehicle and 7 were treated with 
selinexor 15 mg/kg 3× per week. Tumors were measured using calipers and volumes were calculated using the formula tumor volume (mm3) 
= length × width × depth. Mean tumor volume ± standard deviation. The difference in tumor growth rates were statistically significant. 
(B) Following euthanasia, tumors were excised and weighed (vehicle treated = 5 tumors, selinexor treated 6 tumors). The difference in 
weight was statistically significant P ˂ 0.05. Mean tumor weight ± standard deviation. Student’s t test. (C) Western immunoblot analysis 
of vehicle and selinexor treated tumors extracts. Tubulin served as loading control. 
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confirmed the IF results that RB levels are elevated by 
XPO1 inhibition.
Modulation of RB modifies cellular response to 
selinexor 
To test the hypothesis that wt RB plays a role in 
selinexor-mediated decrease in viability, T24 and UM-
UC-3 cells were treated with either control or RB siRNA 
and subsequently treated with vehicle or 0.1uM selinexor 
for 72 hours (Figure 5D). Cell viability following drug 
treatment was scored as percent of vehicle treated cells. 
Depletion of RB curtailed the effect of selinexor treatment. 
Wt RB tumor suppressive function can be impaired 
by cyclin D/CDK4/6-mediated phosphorylation. 
Therefore, inhibition of CDK4/6 results in decreased 
Figure 5: Selinexor alters pocket protein expression in nuclear and cytoplasmic compartments. (A) Representative images 
of p107, p130 and RB (green) IF staining of bladder cancer cells treated with vehicle (V) or selinexor (S) for 48 hours. Tubulin staining 
(red) and DAPI staining (blue) served to define the cytoplasmic and nuclear compartments, respectively. The inserts are magnifications 
of the boxed cells. (B) Quantification of staining intensity of pocket proteins normalized to DAPI. (C) Nuclear and cytoplasmic fractions 
of cell treated with vehicle or 0.15 uM selinexor (UM-UC-3 and T24 cells), 0.25 uM selinexor (J82) and 0.5 uM selinexor (TCCSUP) for 
72 hours were assessed for the expression of RB, p107 and p130. Nup62 and tubulin were used as markers for the nuclear and cytoplasmic 
fractions, respectively. (D) T24 and UM-UC-3 cells transfected with siC or siRB and were treated with vehicle or 0.1 uM selinexor for 
72 hours. The results are shown as percent cell viability comparing drug treated to vehicle treated cells. (E) Palbociclib reduces T24 and 
UM-UC-3 bladder tumor cells viability in a dose dependent manner. (F) Combined selinexor (0.1 uM) and palbociclib (0.5 uM) treatment 
is more effective in reducing viability of cells than either treatment alone where the CI = 1.04 for UM-UC-3 cells and 1.02 for T24 cells 
indicating an additive response. Error bars = ± standard deviation. Student’s t test; * denotes p ≤ 0.05, ** denotes p ≤ 0.01. 
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RB phosphorylation, enhanced RB binding to E2Fs 
and increased transcriptional repression. Since RB 
depletion reduced sensitivity to selinexor, augmenting 
hypophosphorylated levels of RB should enhance 
selinexor efficacy. The CDK4/6 inhibitor palbociclib has 
demonstrated efficacy in limiting growth of cells that 
express wt RB [38]. As expected, T24 and UM-UC-3 cells 
were sensitive to palbociclib in a dose-dependent manner 
(Figure 5E), while J82 and TCCSUP cells were not affected 
by this treatment (Supplementary Figure 2). T24 and UM-
UC-3 cells were treated with vehicle alone, selinexor alone, 
palbociclib alone, or the combination of selinexor (0.1 uM) 
and palbociclib (0.5 uM) for 72 hours. Dual drug treatment 
of T24 and UM-UC-3 cells was significantly more effective 
(Figure 5F) than either single agent suggesting that this 
combination may be an effective treatment strategy for 
bladder malignancies that express wt RB. 
DISCUSSION
Malignancies, including bladder tumors, have 
deregulated expression and localization of multiple 
proteins that collectively promote proliferation and 
survival of transformed cells. Previous studies have 
demonstrated that targeting XPO1-mediated nuclear 
export, which is often augmented in malignancies, is an 
effective strategy to limit tumor cell growth [6, 23]. 
The current study focused on bladder malignancies 
and showed by data mining and tumor tissue array analysis 
that XPO1 is elevated in bladder tumor cells. Cultured 
bladder tumor-derived cells have higher XPO1 levels 
than immortalized SV-HUC1 cells. Bladder tumor cells 
are sensitive to selinexor in a dose dependent manner, 
where the IC50 dose ranged from 0.1–0.5 uM. Selinexor 
efficiently induced apoptosis and growth arrest. These 
results are consistent with previous studies, which showed 
that limiting XPO1 expression induces a growth arrest and 
an apoptotic response [27, 39–41]. The dose of selinexor 
that is sufficient to induce apoptosis and inhibit cell cycle 
progression is significantly lower than what was attained 
in phase 1B clinical trial [42], arguing that this drug may 
be a viable new treatment option for bladder malignancies. 
In vivo studies showed that selinexor was effective in 
reducing tumor growth as a single agent where tumors 
treated with selinexor exhibited a decreased growth rate, 
significantly smaller tumor volume at the termination 
of the study and altered expression of proteins that are 
consistent with growth arrest. 
While all the bladder tumor cells tested were 
sensitive to selinexor treatment, T24 and UM-UC-3 cells, 
which express wt RB, exhibited a heightened response to 
XPO1 inhibition. The importance of XPO1 in RB transport 
is controversial. Initial studies concluded the RB was not 
an XPO1 cargo, but subsequently studies indicated that 
RB phosphorylation affected XPO1-mediated nuclear 
export [32, 43]. The role of XPO1 in trafficking of p107 
and p130 has not been explored. Our immunofluorescence 
and cell fractionation studies addressed the effect of XPO1 
inhibition on the expression level and localization of the 
pocket proteins. XPO1 inhibition has a modest affect in 
altering the abundance of p107 and p130 and a small effect 
in compartmental redistribution. In the bladder tumor cells 
studied RB expression was limited to the nucleus in both 
treated and untreated cells, but selinexor significantly 
increased the abundance of wt RB in the nucleus. It is 
unknown if limiting XPO1 results in RB accumulation 
due to decreased export from the nucleus or if other 
mechanisms are instrumental in elevating RB. A similar 
increase of nuclear p53 in thymic epithelial tumors was 
apparent following selinexor treatment [44]. The increase 
in wt RB was coincident with a decrease in cyclin A, a 
direct E2F/RB target, and cyclin B. These S phase cyclins 
are essential for cell cycle transversal and their decline is 
consistent with a proliferative arrest. Biochemical analyses 
of the resected tumors also showed that selinexor treated 
tumors had reduced XPO1 expression, increased RB and 
p27 levels and a decline of cyclin A, cyclin B and CDK2 
levels, consistent with a growth arrest. 
While RB-mediated growth arrest has been well 
studies, growth arrest can be RB-independent, as we 
observed for the RB mutant bladder cells TCCSUP and J82. 
There are several potential mechanisms of RB-independent 
growth arrest. An increase of CDK inhibitors p21 and p27 
would impedes the activity of cyclin E, A and B, thus 
preventing cell cycle transversal regardless of RB status. 
Treatment of RB mutated cells with histone deacetylase 
inhibitor resulted in growth arrestand flavone treated RB–
/– mouse embryo fibroblasts were able to undergo a growth 
arrest. Cells where RB, p107 and p130  were deleted were 
unable to respond in this manner, arguing the p107 and 
p130 also have a role in growth arrest [45].
The role of RB in apoptosis is far less explored, 
but recent interest in CDK4/6 inhibitors which rely on 
RB tumor suppressive function and induce an apoptotic 
response, has revealed that the mechanism is complex, but 
has been observed in different cellular contexts. In lung 
cancer cells, CDK4/6 inhibition results in suppression 
of IAPs, FOXM1 and survivin and an augmentation 
of SMAC and caspase 3 expression [46]. Induction of 
apoptosis following CDK4/6 inhibition in thyroid cancer 
cells involved a modulation of FOXM1, cyclin A1 and 
myc [47]. CDK4/6 inhibition in melanoma cells resulted in 
apoptosis associated with deregulation of BCL2, BCL2L1, 
BIRC5 and BIM [48]. These studies argue that while RB 
is instrumental in apoptosis, mechanisms are complex and 
cell dependent. Interestingly, we did not detect increased 
PARP cleavage in the drug treated tumors (data not shown). 
During the long-term treatment, the induction of apoptosis 
may result in cell death and elimination of the apoptotic 
cells while the remaining cells undergo a growth arrest.
The hypothesis that RB contributes to selinexor 
sensitivity was tested by modulating RB activity in 
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two different ways in cells expressing wt RB. First, RB 
was ablated by siRNA. Decrease in RB levels reduced 
cellular sensitivity to selinexor. Second, RB activity 
was augmented by inhibiting CDK4/6-mediated RB 
phosphorylation using the CDK4/6 inhibitor palbociclib. 
Treatment of cells with palbociclib enhanced selinexor 
efficacy. Together these analyses argue that in this cellular 
context RB partly mediates the effect of selinexor. Our 
conclusions differ somewhat from previous studies. 
Studies conducted in sarcoma cells found that selinexor-
mediated cell cycle arrest was independent of RB, p53 
and p21 [49] since cells depleted of these proteins or with 
mutant forms of these proteins responded to selinexor 
treatment. In this study there was no increase in RB levels, 
but the authors reported a decrease in RB phosphorylation. 
In models of ovarian and breast cancers, researchers 
concluded that the response to XPO1 inhibition was 
independent of p53, RB, and FOXO [50]. In contrast, 
studies in other contexts reported that p53 and p21 are 
components of the selinexor response [51, 52]. Our results 
and the studies cited above can be reconciled since we 
have found that cells respond to selinexor in the absence 
of wt RB but have a more robust response in the presence 
of wt RB. Moreover, this effect was further enhanced by 
CDK4/6 inhibition. Since RB inactivating mutations are 
found in only 11-20% of bladder malignancies [2], most 
bladder tumor patients could benefit from a therapy that is 
at least partly reliant on the presence of wt RB. Moreover, 
deletions of CDK inhibitors CDKN2A and CDKN2B, 
each of which inhibit CDK4/6 activity occur in over 50% 
of bladder malignancies. Therefore most malignancies 
should be susceptible to CDK4/6 inhibition [53], and 
preclinical studies reported that CDK4/6 inhibition 
of RB positive bladder cancer cells was effective in 
limiting cell proliferation [38]. Our results suggest that 
the combined increase of nuclear RB and decrease of RB 
phosphorylation is an effective combination for limiting 
cell viability and is a potential therapeutic strategy.
MATERIALS AND METHODS
Cell culture and transfections
SV-HUC-1, T24, TCCSUP, J82, and UM-UC-3 cells 
were from American Type Culture Collection (ATCC) 
and used within 6 months of purchase. All cell lines were 
cultured in 10% FBS RPMI-1640 supplemented with 
glutamine and both penicillin and streptomycin at 37C and 
5% CO2. ATCC used the following cell line authentication 
process: Short Tandem Repeat (STR) profiling. The 17 
STR loci plus Amelogenin are amplified using Promega’s 
PowerPlex® 18D System. A comprehensive analysis report 
interprets both karyotypically normal and abnormal cell 
lines, including electropherograms supporting the allele 
calls at each locus, known reference profiling against the 
ATCC STR database and a comprehensive interpretation 
of results.  The cells were tested for mycoplasma within 
the last 6 months using the Lonza Walkersville, Inc 
Mycoalert detection kit (LT07-218). All transfections 
were carried out using Lipofectamine 2000 (Invitrogen 
11668-027) at a concentration of 50nM. The following 
oligonucleotides were used for transfection: siRB 
AACACCCAGGCGAGGUCAGAAUUUU (Dharmacon), 
and control non-targeting oligonucleotide (Dharmacon 
D-001810-10-50). The following drugs were used 
for treatments: palbociclib (in DMSO) (Selleckchem 
PD-0332991 and selinexor which was obtained from 
Karyopharm and dissolved in DMSO.
Tissue microarray
After institutional review board approval, the 
pathologist (R.G.E.) reviewed the histologic sections 
and selected appropriate paraffin blocks. The samples 
were de-identified. A paraffin tissue microarray block 
was constructed of triplicate 60-um core samples using 
the Beecher Instruments Manual Tissue Arrayer. The 
pathologist (R.G.E.) identified areas of appropriate tissue 
on the corresponding histologic sections. Then, 60-um core 
samples were extracted from the specific areas of the donor 
blocks and inserted in the array block. A hematoxylin-
eosin section was prepared and used as a reference to 
interpret the immunostained sections. The bladder tumor 
tissue array consisted of 53 high grade tumors. Each tumor 
was arrayed in triplicate. The bladder PDX tissue array was 
provided by the UCD Cancer Center pathologist (R.G.E.) 
and the generation of the PDX tumors was previously 
reported [26]. 
Immunohistochemistry
Paraffin-embedded blocks were sectioned and 
rehydrated in xylene and graded alcohols. Antigen 
retrieval was performed with 0.1 M citrate buffer at pH 
6.0 for 20 minutes in a 95° C water bath. Slides were 
cooled, followed by sequential rinsing in PBS and 50mM 
Tris HCl, pH 7.6, 150 mM NaCl, Tween 20 (0.1%) 
(TBS-T). Endogenous peroxidase activity was quenched 
by incubation in TBS-T containing 3% hydrogen 
peroxide. Each incubation step was carried out at room 
temperature and was followed by three sequential washes 
(5 minutes each) in TBS-T. Sections were incubated in 
primary antibody, diluted 1:100 in TBS-T containing 
1% ovalbumin and 1mg/ml sodium azide, followed by 
incubations with biotinylated secondary antibody for 
15 minutes, peroxidase-labeled streptavidin for 15 minutes 
(LSAB-2 Agilent, K060911-8) and diaminobenzidine and 
hydrogen peroxide chromogen substrate (Dako Corp. 
Carpentaria CA, USA) for 10 minutes. The sections were 
lightly counterstained with Mayer’s hematoxylin solution 
and mounted with Clear mount (American Mastertech 
Scientific MMCO126). The antibody used was XPO1 
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(CRM1 H-300 sc-5595 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA, dilution 1:100). The images were 
captured at 40× magnification with the Invitrogen EVOS 
FL Auto 2 Cell Imaging System. 
Immunofluorescence
10,000 cells/well were plated in an 8-well chamber 
slide (Nunc Lab-Tek 177445). The following day the 
cells were treated with selinexor or DMSO for 48 hours 
(UM-UC-3 and T24 were treated with 0.15 uM, J82 
was treated with 0.25 uM, and TCCSUP was treated with 
0.5 uM). Then the cells were gently washed twice with 
pre-warmed RPMI-1640 and were fixed with fresh 4% 
paraformaldehyde for 10 minutes at room temperature 
(RT). After fixation, the cells were washed with PBS + 
0.3% Triton-X100 (PBS-Tx) for 10 minutes. Following 
the wash, the cells were incubated with OneBlock 
Western-CL Blocking Buffer (Genesee Scientific 20-313) 
for one hour at RT. The cells were then washed again with 
PBS-Tx for 5 minutes. Primary antibodies were diluted in 
OneBlock and the cells were incubated with the primary 
antibody overnight at 4° C in a humidified chamber (Cell 
Signaling Technology: RB 9309s, tubulin 3873s, tubulin 
2125s; Novus Biologicals: p107 NBP2-33735; Santa 
Cruz Biotechnology: p130 sc-317, CRM1 sc-5595). Cells 
were rinsed twice with PBS and once with PBS-Tx for 
5 minutes each. Secondary antibodies were diluted in 
OneBlock and cells were incubated with the secondary 
antibody for 1 hour at RT in the dark (ThermoFisher 
Scientific: Alexa Fluor 488 A11008, Alexa Fluor 647 
A21235, Alexa Fluor 488 A11001, Alexa Fluor 647 
A21244, Alexa Fluor 660 A21073). Following incubation, 
the cells were washed once with PBS-Tx and twice with 
PBS for 5 minutes each. Finally, the cells were mounted 
with ProLong Diamond Antifade Mountant with DAPI 
(Invitrogen P36971) and left to cure overnight at RT. The 
images were captured at 40x magnification with the 
Invitrogen EVOS FL Auto 2 Cell Imaging System and the 
images were quantified with Fiji [54]. 
Caspase3/7 immunofluorescence assay
55,000 cells/well were plated in 6-well plates. 
The following day the cells were treated with either 
DMSO, 0.1 uM, or 1 uM selinexor for 72 hours. The drug 
containing media was removed and cells were treated 
with media (RPMI-1640 with 10% Fetal Bovine 
Serum and 1% Penicillin and Streptomycin) and CellEvent 
Caspase-3/7 Green (ThermoFisher Scientific R37111) (2 
drops of CellEvent per mL of media) for 30 minutes and 
then imaged at 10× magnification with Invitrogen EVOS 
FL Auto 2 Cell Imaging System. The images were 
then quantified by counting the number of positive cells 
from 4 separate regions for each condition and cell line. 
Proliferation assays
For experiments assessing the growth of cells treated 
with various agents, cells were plated in a 24-well plate at 
10,000 cells/well and the following day treated with drug or 
vehicle. Proliferation was assessed 72 hours later using Cell 
Counting Kit – 8 (CCK-8) (Dojindo CK04). All conditions 
were performed in triplicate and repeated at least twice. 
Data is displayed as the mean ± standard deviation.
For studies using siRB or non-targeting control 
and chemotherapeutic drugs, cells were plated 24 hours 
prior to transfection at 10,000–15,000 cells/well. 24 hours 
post transfection, cells were treated with drugs or vehicle. 
Proliferation was assessed 72 hours later using CCK-8. All 
conditions were performed in triplicate and repeated. Data 
is displayed as the mean ± standard deviation.
Flow cytometry
T24 and UM-UC-3 cells were treated with selinexor 
or vehicle in triplicate. Following 72 hours of treatment, 
cells were harvested, ethanol fixed, and propidium iodide 
(PI) stained (Sigma-Aldrich 11348639001) for cell 
cycle analysis. All flow cytometry was carried out on a 
FACS Calibur flow cytometer (BD). Cell cycle data was 
analyzed using ModFit software. Data is displayed as the 
mean ± standard deviation.
Colony formation assay
T24 and UM-UC-3 cells were plated in a 6-well 
plate at 1,500 cells/well. The following day, cells were 
treated with 0.1 uM selinexor or vehicle (DMSO) for 9 
(J82), 10 (TCCSUP), 11 (UM-UC-3) or 12 (T24) days. 
-, -, - and -. Colonies were stained using crystal violet 
and photographed using an Alpha Innotech MultiImage 
II system. The analyses were performed in triplicate and 
repeated.
Western blot
Cells were lysed in ice cold RIPA buffer 
supplemented with protease inhibitor cocktail (Sigma 
P 8340). Proteins were quantitated using a Bio-rad 
protein assay dye reagent concentrate (BIORAD 
5000006) 10–50 ug of proteins were separated on 8,10 
or 12 % acrylamide-bis SDS-PAGE and transferred to 
nitrocellulose membranes. Membranes were blocked in 
5% milk in PBS-1% Tween 20 or with OneBlock (Genesee 
Scientific 20-313) and incubated with primary antibody 
overnight at 4° C. Membranes were washed with PBS-T 3 
times and incubated with secondary antibody conjugated 
to HRP. Proteins were detected using ECL (Thermo 
Scientific 34096). The following antibodies were used: 
Cell Signaling Technology: PARP (9542s), RB (9309s), 
tubulin (2125s); Santa Cruz Biotechnology: p27 (sc-528), 
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XPO1 (CRM1) (sc-5595), p130 (sc-317), cyclin A (sc-
596), GAPDH (sc-32233), actin (sc-8432) and cdk2 (sc-
163); Covance:  nup62 (MMS-120P); Novus Biologicals: 
p107 (NBP2-33735); Bethyl: cyclin B1 (A305-000A). 
Cell fractionation of cellular lysates was performed with 
the NE-PER nuclear and cytoplasmic extraction reagents 
kit (Thermo Scientific # 78833) per manufacturer’s 
recommendation. 
Mouse studies
All experiments were conducted as approved by UC 
Davis IACUC Committee. 5-6-week old nu/nu athymic 
female mice were obtained from Jackson Laboratory. 
Suspensions of UM-UC-3 cells 106 in 50% Matrigel 
solubilized basement membrane (Fisher #CB40234A) 
were subcutaneously injected to establish xenograft 
tumors. When palpable tumors were observed, mice were 
randomly assigned into the control or treatment group 
and gavaged with vehicle (0.6% Plasdone PVP-29/32 
and 0.6% Poloxamer Pluronic F-68 in water) or selinexor 
(provided by Karyopharm) 15mg/kg three times per week 
for 24 days. The vehicle was prepared fresh weekly and 
the drug was prepared fresh for every use. Tumor volume 
of each tumor was measured 3 times per week length 
× width × depth. If tumors reach 2 cm in any direction 
or if they became ulcerated, the animal was euthanized. 
After euthanasia the tumors were removed and flash 
frozen. For western blot analysis, the tissue was lysed and 
homogenized in ice cold cell lysis buffer (50 mM Tris HCl, 
pH 7.4, 150 mM NaCl, and 1% NP-40, EGTA, EDTA, a 
cocktail of protease inhibitors (Thermo Scientific 78410), 
and phosphatase inhibitors: 20 mM β-glycerol phosphate, 
1 mM Na-orthovanadate, and 10 mM NaF). 
Statistics
A two tailed, unpaired equal variance student’s 
T-test was used to assess differences between samples 
with equal variance and two-tailed unpaired unequal 
variance was used for samples with unequal variance. A 
p < 0.05 was accepted as significant. The combination 
index (CI) was calculated using the Bliss Independence 
model equation: CI = effect of drug A + effect of drug B – 
(effect of drug A X effect drug B/effect of combined AB. 
CI = 1 indicates an additive interaction, CI ˂ 1 indicates 
synergy and a CI ˃ 1 indicates antagonism. GraphPad 
Prism 6 was used to conduct Kaplan–Meier analysis.
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